Wave Life Sciences shares rise 31% due to Q4 loss narrower than expected and increased revenue from GSK and Takeda collaborations.

Wave Life Sciences shares rise 31% after Q4 loss narrower than expected, due to increased revenue from collaborations with GSK and Takeda. Analysts had estimated a loss of $0.23 per share, but the company reported a loss of $0.15 per share. The stock hit its 52-week high of $6.94 on Dec. 6, and has increased 48% in the past 12 months.

March 06, 2024
4 Articles

Further Reading